Who is sponsoring NCT00047502?

NCT00047502 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT00047502?

Interventions in NCT00047502: Lonafarnib (SCH66336), Imatinib Mesylate (Gleevec).

What condition does NCT00047502 study?

NCT00047502 studies Chronic Myelogenous Leukemia.

Is NCT00047502 still recruiting?

NCT00047502 is currently completed. Last updated 7 November 2018.

Last reviewed 2018-11-07 · How we verify

NCT00047502

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia

Completed Phase 1 Last updated 7 November 2018

What this trial tests

Phase 1 trial testing Lonafarnib (SCH66336) in Chronic Myelogenous Leukemia in 23 participants. Completed in 10 April 2006.

Timeline

1 November 2002

Primary endpoint
10 April 2006

10 April 2006

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	23
Start date	1 November 2002
Primary completion	10 April 2006
Estimated completion	10 April 2006
Sites	1 location across United States

Drugs / interventions tested

Lonafarnib (SCH66336) — full drug profile →
Imatinib Mesylate (Gleevec)

Conditions studied

Chronic Myelogenous Leukemia — all drugs for Chronic Myelogenous Leukemia →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

16 and older, any sex, with Chronic Myelogenous Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study if to investigate the effect of lonafarnib (SCH66336) in combination with Gleevec in the treatment of CML.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia-From Molecular Mechanisms to Clinical Relevance.
Alves R, Gonçalves AC, Rutella S, Almeida AM, et al · · 2021 · cited 112× · PMID 34638304 · DOI 10.3390/cancers13194820
Protein lipidation in health and disease: molecular basis, physiological function and pathological implication.
Yuan Y, Li P, Li J, Zhao Q, et al · · 2024 · cited 56× · PMID 38485938 · DOI 10.1038/s41392-024-01759-7
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.
Massimino M, Stella S, Tirrò E, Romano C, et al · · 2018 · cited 51× · PMID 29455672 · DOI 10.1186/s12943-018-0805-1
Development of an effective therapy for chronic myelogenous leukemia.
Woessner DW, Lim CS, Deininger MW. · · 2011 · cited 32× · PMID 22157291 · DOI 10.1097/ppo.0b013e318237e5b7
Potential Approaches <i>Versus</i> Approved or Developing Chronic Myeloid Leukemia Therapy.
Andretta E, Costa C, Longobardi C, Damiano S, et al · · 2021 · cited 23× · PMID 34993151 · DOI 10.3389/fonc.2021.801779
Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia.
Muselli F, Peyron JF, Mary D. · · 2019 · cited 21× · PMID 31717629 · DOI 10.3390/ijms20225616
Shedding Light on Targeting Chronic Myeloid Leukemia Stem Cells.
Houshmand M, Kazemi A, Anjam Najmedini A, Ali MS, et al · · 2021 · cited 10× · PMID 34945101 · DOI 10.3390/jcm10245805

Verify or expand the search:

Other recruiting trials for Chronic Myelogenous Leukemia

Currently open trials in the same condition.

NCT06680661 — ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis · Phase 2 · recruiting
NCT06088888 — TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia · Phase 1 · recruiting
NCT06131801 — Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution · recruiting
NCT05805605 — Allo HSCT Using RIC and PTCy for Hematological Diseases · Phase 2 · recruiting
NCT04877522 — Asciminib Roll-over Study · Phase 4 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00047502 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 7 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00047502.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing